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Since the pathomechanisms of primary open angle glaucoma are still not deﬁned, diﬀerent aspects related to this topic have to be
discussed and further investigated. Possible candidates are the mineralocorticoids, which are known to lower intraocular pressure.
A data search and personal investigations assume a limited role of mineralocorticoids for the development of glaucoma. Speciﬁc
experiments for a ﬁnal conclusion are, however, not yet performed.
1. The Present Deﬁned Risk Factors for
Open Angle Glaucoma Are Poor
Glaucoma comprises a number of diﬀerent pathomech-
anisms leading to a speciﬁc degeneration of the retinal
ganglion cells and changes in the optic nerve head. Primary
open angle glaucoma is the most common form and aﬀects
about 1% of the western population.
To date, the only deﬁned risk factors for the development
of primary open angle glaucoma (POAG) are age and ele-
vated intraocular pressure (IOP). Both factors are complex
and their precise role and regulation are not known. Patho-
morphological correlations discussed for the elevated IOP
are the appearance of “plaque-like extracellular material” in
the human trabecular meshwork [1, 2], “empty spaces/giant
vacuoles” in the juxtacanalicular region next to Schlemm’s
canal [3–5], and the size of Schlemm’s canal itself [6, 7].
T h ea c t i v er o l eo fT Mc e l l si nt h i sr e g u l a t i v ep r o c e s sw a s
considered due to their contractile properties [8, 9]a n dd u e
to intracellular volume regulation [10–12]. Interestingly, the
increased production of aqueous humour alone seems not to
be responsible for elevated intraocular pressure, although a
number of therapies modify this input.
In recent years, a broader understanding of intracellu-
lar volume regulation was gained by the description and
investigation of speciﬁc ion channels and their molecular
regulation. In this context, corticoid hormones played a
crucial role [13, 14]. This paper tries to bring this knowledge
forward to glaucoma pathophysiology.
2. Glucocorticoids Are Known for Their Ocular
Hypertensive Property
Early investigations of steroid hormone function in the eye
were lead by clinical observations of IOP elevation in one-
third of the population after topical cortisone treatment [15,
16]. Persisting ocular hypertension can lead to a speciﬁc type
of open angle glaucoma, the “cortisone-induced” glaucoma
[17, 18] with a typical morphological appearance [19, 20].
Interestingly, systemic elevation of cortisone can slightly
increase IOP but does not lead to a higher risk of glaucoma
development [21]. Therefore, local mechanisms seem to play
a crucial role. One of them is the 11β-hydroxysteroid dehy-
drogenase (HSD) consisting of two isozymes with distinct
diﬀerent functions. HSD1 is the key enzyme for activation
of cortisone; HSD2 leads to inactivation of cortisone in
speciﬁc tissues with aldosterone receptors which could also
be activated by cortisone. To postulate an eﬀect of cortisone,
HSD1 for activation and the glucocorticoid receptor (GR)
should both be present. In the trabecular meshwork GR
and HSD1 were described originally [22], but subsequent
studies only conﬁrmed the presence of GR [23, 24]. From2 Journal of Ophthalmology
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Figure 1: Immunohistochemical staining of the mouse anterior segment with antibodies against α-ENaC (a), β-ENaC (b), and γ-ENaC (c),
immune sera were kindly provided by Bernard Rossier and Christoph Korbmacher, and without primary antibody (d). Note the intense
staining of the trabecular meshwork (TM) and corneal endothelium (arrowheads) with α-a n dγ-ENaC, but not with β-ENaC. Arrows:
conjunctiva and cornea epithelium. The conjunctiva did not show staining with antibodies against γ-ENaC (arrows in (c)).
a functional point of view, glucocorticoids lead to an intra-
cellular volume increase in trabecular meshwork cells [25–
27] and modify the extracellular matrix production [28, 29].
Most surprisingly, one of the extracellular matrix proteins
aﬀected is elevated in all human glaucomatous donor eyes
[30, 31], but physiological studies recently questioned its
role for elevation of trabecular meshwork resistance and IOP
[32, 33]. Thus the cellular volume increase eﬀect of cortisone
has the best evidence to be of pathophysiologic relevance for
IOP increase at present.
3. Mineralocorticoids HaveSome Effects in
the Eye
For a long time, a second group of corticoid hormones, the
mineralocorticoids, were not considered to play any signiﬁ-
cant function in the eye [34]. However, early investigations
mentioned that the aldosterone-antagonist spironolacton
led to a decrease of intraocular pressure in glaucomatous
patients [35]. Mirshahi and coworkers were the ﬁrst to
describe mineralocorticoid hormone receptors (MR) in the
retina and all epithelial cells of the eye [36, 37]. To consider
speciﬁc aldosterone function, the presence of HSD2 next
to the MR is necessary. The presence of MR and HSD2 in
the trabecular meshwork is described controversially [22–
24]. Mineralocorticoid eﬀects are thought to be mediated
by epithelial sodium channels (EnaC) [38, 39], which are
also present at numerous places in the anterior eye segment
[40–43]. These channels might serve two diﬀerent functions:
one is ﬂuid secretion from the ciliary epithelium (increase of
aqueous humour formation), and the other is regulation of
the trabecular meshwork resistance by volume regulation of
the trabecular meshwork cells. The ﬁrst is the most widely
suggested mechanism for aldosterone [44] since a consistent
presence of MR and a strong evidence for the presence of
HSD2 are reported in ciliary epithelium cells [22–24]. If the
trabecular meshwork is also a target tissue for aldosteron
remains to be determined.
4.CanMouseEyeModelsHelpConcerning
Mineralocorticoid Effects?
A number of mouse models were established to study
mineralocorticoid eﬀects but no data exists about the eyes
of these animals. The existing genetically altered mice show
either an overexpression of the MR [44–46], a knockout of
HSD2 [47], or alterations of the ENaC ion channels (Liddle’s
syndrome) [48, 49].
Unfortunately, there is no data in mouse eyes for the
presence and distribution of MR and HSD2. Personal inves-
tigations on the distribution of ENaC in the mouse anterior
eye segment showed intense staining for α-a n dγ-EnaC, but
no staining for β-EnaC in the trabecular meshwork, while
the ciliary epithelium showed only a weak staining reaction
(Figure 1).Journal of Ophthalmology 3
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Figure 2: Proposed mechanisms by which mineralocorticoids play
a role in glaucoma.
Overexpression of MR was induced in B6D2 animals.
During embryogenesis, MR overexpression led to massive
changes in the anterior eye chamber due to epidermal
atrophy in these nonviable puppets [46]. Unfortunately,
these animals have a DBA/2J background leading to changes
in the chamber angle beginning at 3 months of age. Personal
investigations on the eyes of 6-months-old transgenic ani-
mals (P1.hMR and P2.hMR from [44, 45]) show massive
synechiae of the iris, atrophy of the ciliary body, strong
pigmentation of the chamber angle, and loss of retinal
ganglion cells. These ﬁndings match with ﬁndings observed
in other DBA strains [50–52]. Speciﬁc mineralocorticoid
related changes could not be observed. Knockout of HSD2
was performed in C57/Bl6 mice.
The mouse model established for Liddle’s syndrome has
an altered β-EnaC subunit. There seems to be no eﬀect of
aldosteron on the α-EnaC subunit in these animals [53].
Personal investigations on eyes of these animals revealed
a normal morphology. Schlemm’s canal was widely open,
trabecular meshwork cells were not swollen, abnormalities
in the anterior and posterior eye segments could not be
detected. Since the normal mouse eye does not express the
β-EnaC subunit in the trabecular meshwork and inner eye
surfaces, these results are not surprising.
Concluding, at this stage of research mouse models
do not help to answer questions related to the role of
mineralocorticoids in the eye.
5.SpeciﬁcMineralocorticoid Dysfunctions
Also Existinthe Human: Howabout Ocular
Pathology inThese Patients?
A number of conditions are known in the human associated
with mineralocorticoid dysfunction. A relation to ocular
pathologies was tested.
Hyperaldosteronism is a common, but rarely diagnosed
condition (estimated 1.5–3.5% of the entire population
in Germany [54]). The induced high blood pressure can
aﬀect the eye but not in a glaucoma-speciﬁc way. There
are no functional changes in the eye related to this general
condition. It remains to be determined if these patients show
any association to glaucoma.
Apparent mineralocorticoid excess is a condition with
lack of HSD2 and subsequently increased activation of MR
[55]. There is no report in the literature that any of the
diagnosed patients suﬀered from either elevated IOP or
glaucoma.
Pseudohypoaldosteronismtype1isrelatedtoareduction
of alpha ENaC function [56, 57]. A communication with
Prof. Hanukoglu (Tel Aviv) revealed that these persons do
not complain of any speciﬁc eye symptoms. An extended
ocular examination of his oldest patient at that time (19
years old) showed normal intraocular pressure (17mmHg),
anormalanteriorchamberincludingthechamberangle,and
a normal OCT of the nerve ﬁbers in the retina. The only
ﬁnding was a slightly increased corneal thickness (570μm).
If this ﬁnding is related to a reduced function of the corneal
endothelium remains to be determined.
6. Is There Any Mineralocorticoid Input to
Glaucoma Pathophysiology at Present?
Systemic application of mineralocorticoids to glaucoma
patients shows no changes in the IOP in most of the
cases [58, 59]. However, single individuals react with a
high increase in intraocular pressure [58]. Unfortunately,
these “mineralocorticoid-sensitive” persons are not further
characterized. They could constitute a new subgroup of
ocular hypertension or glaucoma patients, but more clinical
data has to be collected to deﬁne these persons.
The lack of general agonist eﬀects combined with the
mild IOP decrease of antagonists [35] points to a possible
role of mineralocorticoids for glaucoma therapy but not for
general glaucoma pathophysiology. The narrowed role is also
supported by the negative ﬁndings in the animal models and
the various human conditions described above. The thera-
peutic eﬀect of mineralocorticoid antagonists seems mainly
mediated by a decrease of aqueous humour formation [36].
If there is some eﬀect on the outﬂow pathway remains open.
One additional aspect of mineralocorticoid function is
venoconstriction and thus an increase in postcapillary pres-
sure [60, 61]. Venoconstriction could also be of relevance for
elevated intraocular pressure as known from rat glaucoma
models[62].Ifmineralocorticoidmediatedvenoconstriction
is also present in limbal veins remains to be determined.
Ad i ﬀerent venous sensitivity could be a criterion for the
above hypothesized mineralocorticoid-sensitive subgroup of
humans.
7. Conclusion
The proposed mechanisms by which mineralocorticoids play
a role in glaucoma are summarized in Figure 2. While there
is some evidence that the ciliary epithelium is aﬀected by
mineralocorticoids, the role of the trabecular meshwork cells
and of the limbal veins remains to be determined. Hopefully
this paper attracts more scientists and clinicians for further
research in the area of mineralocorticoids with respect to the
pathogenesis of glaucoma.4 Journal of Ophthalmology
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